| 1 |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al. · Autophagy
Open access2,467 authors |
2 Jan 2016 |
6,023 |
| 2 |
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert Louis Ferris et al. · New England Journal of Medicine
Open access |
9 Oct 2016 |
5,189 |
| 3 |
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky et al. · Autophagy
Open access1,270 authors |
Apr 2012 |
4,068 |
| 4 |
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera et al. · New England Journal of Medicine
Open access |
10 Sep 2008 |
3,762 |
| 5 |
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
3,488 |
| 6 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Thierry Conroy et al. · New England Journal of Medicine
Open access |
19 Dec 2018 |
2,918 |
| 7 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 8 |
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,495 |
| 9 |
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
18 Feb 2015 |
2,183 |
| 10 |
Hypoxia signalling in cancer and approaches to enforce tumour regression
Jacques Pouysségur, Frédéric Dayan, Nathalie M. Mazure · Nature
|
24 May 2006 |
1,671 |
| 11 |
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Éric Pujade-Lauraine, Felix Hilpert, Beatrice E. Weber et al. · Journal of Clinical Oncology
|
18 Mar 2014 |
1,650 |
| 12 |
Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
Laëtitia Marisa et al. · PLoS Medicine
Open access |
21 May 2013 |
1,590 |
| 13 |
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot et al. · The Lancet Oncology
|
20 Oct 2010 |
1,556 |
| 14 |
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
Thierry Conroy et al. · The Lancet Oncology
Open access |
15 Apr 2021 |
1,363 |
| 15 |
HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia
Edurne Berra, Emmanuel Benizri, Amandine Ginouvès et al. · The EMBO Journal
Open access |
11 Aug 2003 |
1,361 |
| 16 |
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent, Alba Ariela Brandes, Martin Taphoorn et al. · Journal of Clinical Oncology
Open access |
16 Oct 2012 |
1,236 |
| 17 |
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima et al. · Journal of Clinical Oncology
|
7 Oct 2020 |
1,199 |
| 18 |
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigné et al. · The Lancet
|
Apr 2012 |
1,016 |
| 19 |
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain, Sung‐Bae Kim, Javier Cortés et al. · The Lancet Oncology
Open access |
18 Apr 2013 |
1,012 |
| 20 |
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
Heinz Ludwig, Simon Van Belle, Peter J. Barrett-Lee et al. · European Journal of Cancer
|
17 Sep 2004 |
939 |
| 21 |
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al. · New England Journal of Medicine
Open access |
22 Sep 2021 |
916 |
| 22 |
Shear-wave Elastography Improves the Specificity of Breast US: The BE1 Multinational Study of 939 Masses
Wendie A. Berg, David Owen Cosgrove, Caroline J Doré et al. · Radiology
|
26 Jan 2012 |
844 |
| 23 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
Karim S. Fizazi et al. · The Lancet
Open access |
Apr 2022 |
823 |
| 24 |
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert Louis Ferris et al. · Oral Oncology
Open access |
17 Apr 2018 |
813 |
| 25 |
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Joseph M. Connors et al. · New England Journal of Medicine
Open access |
10 Dec 2017 |
792 |
| 26 |
Radiotherapy for Glioblastoma in the Elderly
Florence Keime-Guibert, Olivier Louis Chinot, Luc Taillandier et al. · New England Journal of Medicine
|
11 Apr 2007 |
791 |
| 27 |
p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1
Darren E. Richard, Edurne Berra, Emmanuel Gothié et al. · Journal of Biological Chemistry
Open access |
Nov 1999 |
787 |
| 28 |
Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity
Eoin P. Cummins, Edurne Berra, Katrina M. Comerford et al. · Proceedings of the National Academy of Sciences
|
18 Nov 2006 |
785 |
| 29 |
Hypoxia and cancer
M. Christiane Brahimi-Horn, Johanna Chiche, Jacques Pouysségur · Journal of Molecular Medicine
Open access |
19 Nov 2007 |
776 |
| 30 |
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology
|
23 Oct 2020 |
763 |
| 31 |
Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH
Johanna Chiche, Karine Ilc, Julie Laferrière et al. · Cancer Research
|
31 Dec 2008 |
756 |
| 32 |
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
Martin J. van den Bent, Alain Carpentier, Alba Ariela Brandes et al. · Journal of Clinical Oncology
|
16 Jun 2006 |
750 |
| 33 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology
|
Nov 2012 |
748 |
| 34 |
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial
Gwénaëlle Gravis et al. · The Lancet Oncology
|
8 Jan 2013 |
747 |
| 35 |
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology
|
May 2014 |
727 |
| 36 |
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Martin Jean Schlumberger, Bogdan Catargi, Isabelle Borget et al. · New England Journal of Medicine
Open access |
2 May 2012 |
698 |
| 37 |
Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer
Johanna Chiche, M. Christiane Brahimi-Horn, Jacques Pouysségur · Journal of Cellular and Molecular Medicine
Open access |
Apr 2010 |
675 |
| 38 |
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology
Open access |
12 Apr 2017 |
620 |
| 39 |
Hypoxia-induced autophagy: cell death or cell survival?
Nathalie M. Mazure, Jacques Pouysségur · Current Opinion in Cell Biology
ReviewOpen access |
22 Dec 2009 |
620 |
| 40 |
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
Marius Ilié, Élodie Long-Mira, Coraline Bence et al. · Annals of Oncology
Open access |
20 Oct 2015 |
595 |
| 41 |
The Global Breast Cancer Burden: Variations in Epidemiology and Survival
Gabriel N. Hortobágyi, Jaime de la Garza Salazar, Kathleen I. Pritchard et al. · Clinical Breast Cancer
|
Dec 2005 |
594 |
| 42 |
Non-hypoxic pathway mediates the induction of hypoxia inducible factor 1 alpha (HIF-1 alpha ) in vascular smooth muscle cells
Darren E. Richard · Journal of Biological Chemistry
|
2 Jun 2000 |
585 |
| 43 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
Élisabeth Quoix et al. · The Lancet
|
13 Aug 2011 |
578 |
| 44 |
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
Andrea Varrone, Susanne Asenbaum, Thierry Vander Borght et al. · European Journal of Nuclear Medicine and Molecular Imaging
Open access |
16 Oct 2009 |
550 |
| 45 |
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Australian Cancer Study et al. · Nature Genetics
Open access443 authors |
27 Mar 2013 |
544 |
| 46 |
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Sylvie Bonvalot et al. · The Lancet Oncology
Open access |
8 Jul 2019 |
537 |
| 47 |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n et al. · The Lancet Oncology
|
16 May 2017 |
531 |
| 48 |
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem et al. · Annals of Oncology
Open access |
23 Jul 2018 |
508 |
| 49 |
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Riccardo Soffietti, Brigitta G. Baumert, Lorenzo Bello et al. · European Journal of Neurology
Open access |
16 Aug 2010 |
506 |
| 50 |
The natural history of Caenorhabditis elegans
Marie‐Anne Félix, Christian Braendle · Current Biology
Open access |
Nov 2010 |
494 |